Universe Pharmaceuticals INC Announces Strategic Partnership with Lian-Ou Health to Develop its Digital Marketing and Sales on E-Commerce Platforms

2 years ago

Ji’an, Jiangxi, China, March 30, 2022 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the “Company”) (Nasdaq: UPC), a pharmaceutical producer and…

Mapi Pharma Receives U.S. Patent Covering Methods of Suppressing or Alleviating Primary or Secondary Progressive Multiple Sclerosis with a Sustained Release Glatiramer Acetate Depot

2 years ago

NESS ZIONA, Israel, March 30, 2022 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company…

INmune Bio, Inc. Announces Company’s CSO Dr. Mark Lowdell to Co-Host the “NK Cells in Solid Tumors” Workshop at Innate Killer Summit

2 years ago

The Company also Plans on Sharing INKmune™ Patient Case StudiesBoca Raton, Florida, March 30, 2022 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ:…

Compass Therapeutics Announces Presentation on CTX-8371, A Bispecific Antibody Targeting PD-1 and PD-L1, at the 2022 AACR Annual Meeting in New Orleans

2 years ago

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biotechnology company developing proprietary antibody-based…

PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology

2 years ago

BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of…

Morphic to Participate in BMO Inflammation and Immunology Spotlight Series Panel

2 years ago

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of…

Alignment Healthcare Celebrates One Year as a Public Company with Significant Revenue, Product and Membership Growth, Doubled Geographic Footprint

2 years ago

ORANGE, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- Alignment Healthcare (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, marked one year…

VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis

2 years ago

VYN201 demonstrated statistically significant improvement in treatment response for both endpoints at 1mg/kg and 10mg/kg dosesVYN201 also demonstrated numerically superior results…

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

2 years ago

All enrolled patients were 2nd line metastatic non-small cell lung carcinoma (NSCLC) patients that had confirmed progressive disease after prior…

Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327

2 years ago

Highlights: 10 subjects in cohort four intravenously dosed; RECCE® 327 at 1,000mg, indicating to be safe and well-tolerated Independent Safety…

Show more Posts
Show previous Posts